Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lee's Pharmaceutical Holdings Limited is a Hong Kong-based biopharmaceutical company focused on developing and commercializing innovative therapies in the areas of oncology, respiratory, and infectious diseases. Its competitive position is strengthened by partnerships with global pharmaceutical firms and a robust pipeline of proprietary products, particularly in the Chinese market.
Lee's Pharmaceuticals generates revenue primarily through the sale of proprietary drugs, leveraging its strong R&D capabilities and strategic partnerships to enhance its product offerings. The company benefits from pricing power in the Chinese market due to its innovative therapies and established relationships with healthcare providers.
Approval and launch of new drugs in China, particularly in oncology
Partnership announcements with global pharmaceutical companies
Changes in regulatory policies affecting drug pricing
Market demand for respiratory therapies
Regulatory changes in drug approval processes
Technological disruption in drug development
Increasing competition from generic drug manufacturers
Emergence of new biotech firms with innovative therapies
Low ROE (4.6%) indicating potential inefficiencies in capital utilization
Dependence on successful commercialization of a limited number of products
moderate - The company's performance is somewhat linked to GDP growth as healthcare spending tends to rise during economic expansions.
The company's low debt levels (Debt/Equity of 0.15) mean that rising interest rates have minimal impact on financing costs, but could affect overall market sentiment and valuation multiples.
minimal - The company does not heavily rely on credit for operations due to its solid cash flow generation.
growth - Investors are likely attracted to the potential for high returns from innovative drug development.
moderate - Historical volatility is expected to be moderate due to the nature of the pharmaceutical industry and its dependency on regulatory approvals.
